RxDoctor Payments Data

Milton Garcia, MD

Nephrology · Arecibo, PRNPI 1194820431

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $4,065 of the $6,753 with a category attached, or 60.2%. 20 manufacturers reported payments, led by Johnson & Johnson at 35.0% of the total. Reporting peaked in 2024 at $2,612 and has fallen 88.4% since, to $302 in 2025.

$6,753in general payments, 2019–2025

Across 39 payments — averaging $173.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$2K
  • Fennec Pharmaceuticals, Inc.$393
  • Mallinckrodt Hospital Products Inc.$219
  • Calliditas Therapeutics US Inc.$185
  • Bayer$182
  • plus $1K from 14 others

What the payments were for

  • Consulting fees$4,06560%
  • Travel & lodging$220%
  • Food & beverage$2,50437%
  • Education$1622%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,753 in reported general payments places this provider in the 85th percentile of 161 nephrology providers in Puerto Rico.

See all nephrology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$9,825
Medicare patients
24
Services billed
95

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol194$114,169
KerendiaFinerenone167$111,549
TrulicityDulaglutide27$26,684
JardianceEmpagliflozin22$13,574
TradjentaLinagliptin15$7,923
Sevelamer Carbonate19$2,507
Calcium Acetate36$2,098
LantusInsulin Glargine,hum.Rec.Anlog24$1,877
Valsartan72$1,386
Irbesartan46$797
Carvedilol48$282
Chlorthalidone23$203
Atorvastatin Calcium26$133
Metformin Hcl18$111
Levofloxacin14$103

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$168$114,169194 claims
BayerKerendia$182$111,549167 claims
Lilly USA, LLCTrulicity$131$26,68427 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 161 nephrology providers in Puerto Rico.

Other nephrology in Arecibo

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →